Ogasawara Masahiro, Miyashita Mamiko, Yamagishi Yuka, Ota Shuichi
Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Institute for Artificial Organ, Transplantation and Cell Therapy, Sapporo, Japan.
Ther Apher Dial. 2022 Jun;26(3):537-547. doi: 10.1111/1744-9987.13828. Epub 2022 Mar 10.
The prognosis of patients with relapsed or refractory acute leukemia is poor. In the present pilot study, we treated relapsed or refractory acute leukemia patients with Wilms' tumor 1 (WT1) peptide-loaded dendritic cells (DCs) and examined safety, clinical and immunological responses.
Eleven eligible patients were enrolled. DCs were administered every 2-3 weeks with OK-432 adjuvant.
The treatment was well tolerated. The reduction of leukemia cells or the expression of WT1 mRNA was observed in four patients which was maintained for a significant period of time. All the responding patients manifested immune responses against WT1 which might be related to clinical outcome. Decreases in the absolute number of regulatory T cells were observed following vaccination, indicating that DC vaccinations may contribute to the reversal of immunosuppression.
These results indicate that DC-based immunotherapy is safe and feasible for patients with acute leukemia.
复发或难治性急性白血病患者的预后较差。在本试点研究中，我们用负载肾母细胞瘤1（WT1）肽的树突状细胞（DC）治疗复发或难治性急性白血病患者，并检测安全性、临床和免疫反应。
招募了11名符合条件的患者。每2 - 3周给予DC并佐以OK - 432。
治疗耐受性良好。4名患者出现白血病细胞减少或WT1 mRNA表达降低，且持续了较长时间。所有有反应的患者均表现出针对WT1的免疫反应，这可能与临床结果相关。接种疫苗后观察到调节性T细胞绝对数量减少，表明DC疫苗接种可能有助于逆转免疫抑制。
这些结果表明，基于DC的免疫疗法对急性白血病患者是安全可行的。
